Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.

ABSTRACT:

Aims

Immune activation, which is characteristic of both tuberculosis (TB) and human immunodeficiency virus (HIV) infection, is associated with impaired drug metabolism. We tested the hypothesis that elevated levels of systemic immune activation among adults with HIV/TB initiating antiretroviral therapy (ART) would be associated with impaired clearance of isoniazid.

Methods

We conducted a prospective observational study of isoniazid pharmacokinetics (PK) and systemic immune activation prior to and 1 month after ART initiation. Nonlinear mixed effects analysis was performed to measure the covariate effect of immune activation on isoniazid clearance in a model that also included N-acetyltransferase-2 (NAT-2) genotype and interoccasional variability on clearance (thereby analyzi

SUBMITTER: Vinnard C 

PROVIDER: S-EPMC5346858 | biostudies-literature | 2017 Apr

REPOSITORIES: biostudies-literature